Drugs / bi-4SCAR CD19/22 T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05432882 | Jun 2026 → Dec 2029 expected | B-cell neoplasm | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bi-4SCAR CD19/22 T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05432882 ↗ |
| Action | Deplete | “recognize and kill tumor cells” NCT05432882 ↗ |
| Modality | Cell therapy | “genetically modified T cells” NCT05432882 ↗ |
| Route | Intravenous | “via IV” NCT05432882 ↗ |
| Target | CD19 | “The CAR molecules enable the T cells to recognize and kill tumor cells through the recognition of a surface antigen, CD19 or CD22, which is expressed at high levels on tumor...” NCT05432882 ↗ |
| Target | CD22 | “The CAR molecules enable the T cells to recognize and kill tumor cells through the recognition of a surface antigen, CD19 or CD22, which is expressed at high levels on tumor...” NCT05432882 ↗ |